Abstract
5-Hydroxytryptophan (5-HTP) has been used clinically for more than 30 yr (Birdsall, 1998). Sales and awareness of 5-HTP increased in 1989 after the Food and Drug Administration (FDA) banned its precursor, l-tryptophan, because of its association with eosinophilia-myalgia syndrome. Since then, 5-HTP has been marketed as a safe alternative to l-tryptophan.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Birdstall TC. 5-hydroxytryptophan: a clinically-effective serotonin precursor. Alt Med Rev 1998;3:271–80.
Cangiano C, Laviano A, Del Ben M, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. Int J Obes 1998; 22: 648–54.
Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990; 18: 201–9.
Coleman M. Infantile spasms associated with 5-hydroxytryptophan administration in patients with Down’ s syndrome. Neurology 1971; 21: 911–9.
Currier RD. A treatment for ataxia [editorial]. Arch Neurol 1995; 52: 449.
FDA. FDA talk paper: Impurities confirmed in dietary supplement 5-hydroxy-L-tryptophan. August 31, 1998. Available from: URL: http://www.vm.cfsan.fda.gov/-1rd/tp5htp/html. Accessed February 12, 2002.
Gwaltney-Brant SM, Albretsen JC, Khan SA. 5-Hydroxytryptophan toxicosis in dogs: 21 cases (1989–1999). J Am Vet Med Assoc 2000; 15: 1937–40.
Health Source Plus. Possible link found between supplements and serious illness. NCRHI newsletter 1999; 22: 1–2.
Hermes AE. Hydroxytryptophan (drug evaluation): In: Hutchinson TA, Shahan DR, Eds. DRUGDEX ® System. Greenwood Village, CO: MICROMEDEX (edition expires December, 2001 ).
Joly P, Lampert A, Thomine E, Lauret P. Development of psuedobullous morphea and sclerodema-like illness during therapy with L-5-hydroxytryptophan and carbidopa. J Am Acad Dermatol 1991; 25: 332–3.
Kahn RS, Westenberg HG, Verhoeven WM, et al. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 1987; 2: 33–45.
Klarskov K, Johnson KL, Benson LM, et al. Eosinophilia-myalgia syndrome case-associated contaiminants in commercially available 5-hydroxytryptophan. Adv Exp Med Biol 1999; 467: 461–8.
Medsger TA Jr. Tryptophan-induced eosinophilia-myalgia syndrome. N Engl J Med 1990; 322: 926–8.
Meyer JS, Welch KM, Deshmukh VD, et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer’s disease. JAGS 1977; 25: 289–98.
Michelson D, Page SW, Casey R, Trucksess MW, Love LA, Milstien S, et al. An eosinophiliamyalgia syndrome related disorder associated with exposure to L-5-hydroxyryptophan. J Rheumatol 1994; 21: 2261–5.
Nicolodi M, Sicuteri F. L-5-hydroxytryptophan can prevent nociceptive disorders in man. Adv Exp Biol 1999; 467: 177–82.
Pueschel SM, Reed RB, Cronk CE, Goldstein BI. 5-Hydroxytryptophan and pyridoxine. Their effects in young children with Down’s syndrome. Am J Dis Child 1980; 134: 838–44.
Pöldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. Psychopathology 1991; 24: 53–81
Reynolds JEF, ed. Martindale: the extra pharmacopoeia, 31St ed. London: Royal Pharmaceutical Society; 1996. p. 328.
Ribeiro CA, For the Portugese Head Society. L-5-hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. Headache 2000; 40: 451–6.
Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software.
Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness during therapy with L-5-hydrxytryptophan and carbidopa. N Engl J Med 1980; 303: 782–7.
Sverd J, Kupietz SS, Winsberg BG, et al. Effects of L-5-hydroxytryptophan in autistic children. J Autism Child Schizophr 1978; 8: 171–80.
Trouillas P, Serratrice G, Laplane D, et al. Levorotatory form of 5-hydroxytryptophan in Friedrich’s ataxia: results of a double-blind drug-placebo cooperative study. Arch Neurol 1995; 52: 456–60.
Van Praag J, Korf J, Dols L, Schut T. A pilot study of the predictive value of the probenecid test in application of 5-hydroxytryptophan as antidepressant Psychopharm 1972; 25: 14–21.
Wessel K, Hermsdörfer, Deger K, et al. Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases. Arch Neurol 1995; 52: 451–5.
Westenberg HGM, Gerritsen TW, Meijer BA, van Praag HM. Kinetics of L-5-hydroxytryptophan in healthy subjects. Psychiatry Res 1982; 7: 373–85.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bowers, K., Cupp, M.J., Tracy, T.S. (2003). 5-Hydroxytryptophan (5-Hydroxy-l-Tryptophan, l-5-Hydroxytryptophan, Oxitriptan) . In: Cupp, M.J., Tracy, T.S. (eds) Dietary Supplements. Forensic Science and Medicine. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-303-3_16
Download citation
DOI: https://doi.org/10.1007/978-1-59259-303-3_16
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9726-7
Online ISBN: 978-1-59259-303-3
eBook Packages: Springer Book Archive